Drug Search Results
More Filters [+]

Reproterol

Alternative Names: reproterol
Latest Update: 2009-04-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRB2 Agonist,PDE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Ireland | Italy | Pakistan | Portugal | Russia

Approved Indications: None

Known Adverse Events: None

Company: MEDA Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Reproterol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma, Exercise-Induced|Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AERIA

P2

Completed

Asthma

2008-10-30

AERIA

P2

Completed

Asthma, Exercise-Induced

2008-10-01

35%

Recent News Events

Date

Type

Title